Related Experiment Video
Updated: May 9, 2026

Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds
Published on: February 16, 2022
Nicotine-Mediated Redox and Nitrosative Stress in Cardiorenal Health
Marharyta Semenikhina1,2, Adam Jones3, Vishwajeeth Pasham4
1Division of Nephrology, Department of Medicine (M.S., M.N.B., O.P.), Medical University of South Carolina, Charleston, SC.
None:
Nicotine exposure is increasingly widespread due to the expansion of the use of noncombustible tobacco and nicotine-replacement products; yet nicotine is still being framed as an addictive but relatively benign compound. This review synthesizes clinical and experimental evidence linking nicotine exposure to cardiorenal disease, emphasizing that risks persist after cessation. We discuss here a central novel concept that damage caused by nicotine in tissues is not determined solely by receptor signaling, as nicotine exists in chemical forms capable of strong receptor-independent membrane diffusion. Mechanistically, we highlight convergent pathways of nicotine-induced cellular injury, focusing on redox stress and underscoring major limitations in the field, such as the lack of studies in epithelial cells. We further emphasize the emerging paradigm that links nicotine and nitric oxide synthase (NOS) biology, in which reduced nitric oxide bioavailability, NOS uncoupling, and peroxynitrite-mediated protein nitration represent underappreciated drivers of persistent cardiorenal injury in response to nicotine. Finally, we outline gaps and research priorities needed to identify therapeutic strategies that specifically mitigate nicotine-driven oxidative and nitrosative injury in vulnerable populations with hypertension, diabetes, and chronic kidney disease.
Related Concept Videos
Redox Reactions
Bioactivation and Tissue Toxicity
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
Coronary Artery Disease II: Pathophysiology
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
